FDA Approved Products
99 products with lifecycle intelligence, competitive pressure scores, and patent timelines.
AIR
air
Launch
INHALATION · GAS
2026
NDA30/100
AVGEMSI
gemcitabine
Launch
Viatris (2)
INTRAVENOUS · SOLUTION
breast cancerlung cancer+2
2025
NDA30/100
AVOPEF
etoposide
Launch
Viatris (2)
INTRAVENOUS · INJECTABLE
refractory testicular cancer in adult patientslung cancer
2026
NDA30/100
BENDAMUSTINE HYDROCHLORIDE
bendamustine hydrochloride
Launch
Dr. Reddy's Laboratories
INTRAVENOUS · SOLUTION
within six months of treatment with rituximaba rituximab-containing regimen+2
2025
NDA30/100
BYSANTI
milsaperidone
Launch
Vanda Pharmaceuticals
ORAL · TABLET
2026
NDA30/100
CAMCEVI ETM
leuprolide mesylate
Launch
Accord Biopharma
SUBCUTANEOUS · EMULSION
2025
NDA30/100
CARBON DIOXIDE, USP
carbon dioxide
Launch
GAS
2025
NDA30/100
CARBON DIOXIDE, USP
carbon dioxide
Launch
Martin Pharmaceuticals
INHALATION · GAS
2025
NDA30/100
CARBON DIOXIDE, USP
carbon dioxide
Launch
INHALATION · GAS
2025
NDA30/100
DEHYDRATED ALCOHOL
dehydrated alcohol
Launch
INTRAVENOUS · SOLUTION
2025
NDA30/100
DESMODA
desmopressin acetate oral solution
Launch
ORAL · SOLUTION
nephrogenic diabetes insipiduscentral diabetes insipidus
2026
NDA30/100
DULOXETINE
duloxetine
Launch
Almatica Pharma
CAPSULE, DELAYED RELEASE
the following conditions: Major depressive disorder (MDD) in adults ( ) Generalized anxiety disorder (GAD) in adultsolder ( ) Diabetic peripheral neuropathic pain (DPNP) in adults ( ) Fibromyalgia (FM) in adults+2
2026
NDA30/100
E-Z-DISK
barium sulfate
Launch
Bracco
ORAL · TABLET
2025
NDA30/100
ESCITALOPRAM
escitalopram
Launch
Almatica Pharma
ORAL · CAPSULE
anxiety
2025
NDA30/100
FAMOTIDINE
famotidine
Launch
Sagent Pharmaceuticals
INTRAVENOUS · SOLUTION
hospitalized pediatric patients 1 year of ageolder+2
2025
NDA30/100
FAVLYXA
fluorouracil
Launch
Viatris (2)
INTRAVENOUS · SOLUTION
Rectum () Adenocarcinoma of the Breast () Gastric Adenocarcinoma () Pancreatic Adenocarcinoma () 1
2026
NDA30/100
JASCAYD
nerandomilast
Launch
Boehringer Ingelheim
ORAL · TABLET
2025
NDA30/100
LASIX ONYU
furosemide
Launch
Innovation Pharmaceuticals
SUBCUTANEOUS · SOLUTION
edema in adult patients with chronic heart failure
2025
NDA30/100
LOPRESSOR
metoprolol tartrate
Launch
ORAL · TABLET
the treatment of hemodynamically stable adult patients with myocardial infarctionto reduce the risk of cardiovascular mortality+1
2025
NDA30/100
LOPRESSOR
metoprolol tartrate
Launch
Rubicon Biotechnology
ORAL · SOLUTION
hypertension in adult patientsto lower blood pressure+7
2025
NDA30/100
MUCINEX 12HR COLD & FEVER MULTI-SYMPTOM
dextromethorphan hydrobromide; guaifenesin; naproxen sodium
Launch
ORAL · TABLET, EXTENDED RELEASE
2025
NDA30/100
PHENYLEPHRINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE
phenylephrine hydrochloride injection, solution
Launch
Dr. Reddy's Laboratories
INTRAVENOUS · SOLUTION
2025
NDA30/100
PIPERACILLIN AND TAZOBACTAM AND SODIUM CHLORIDE IN DUPLEX CONTAINER
piperacillin and tazobactam and sodium chloride
Launch
B. Braun
INTRAVENOUS · POWDER
older) for the treatment of appendicitis (complicated by ruptureabscess)+13
2025
NDA30/100
PREZCOBIX
darunavir and cobicistat
Launch
Johnson & Johnson
ORAL · TABLET, FOR SUSPENSION
2026
SMNDA30/100
Page 1 of 5Next →